Showing results (331-340 of 407) with videos related to
Sort By:
Pageof 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2014
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancerMatthew D Burstein, Anna Tsimelzon, Graham M Poage, et al.Genome Medicine|October 16, 2014
Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patientsSarah Scollon, Katie Bergstrom, Robin A Kerstein, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 26, 2011
To share or not to share: a randomized trial of consent for data sharing in genome researchAmy L McGuire, Jill M Oliver, Melody J Slashinski, et al.Nature Communications|August 8, 2014
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancersJamunarani Veeraraghavan, Ying Tan, Xi-Xi Cao, et al.Virchows Archiv : an International Journal of Pathology|January 7, 2022
Contamination of personal protective equipment during COVID-19 autopsiesJohanna M Brandner, Peter Boor, Lukas Borcherding, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patientsJenny C Chang, Eric C Wooten, Anna Tsimelzon, et al.Proceedings of the National Academy of Sciences of the United States of America|April 18, 1998
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexesR M Lavinsky, K Jepsen, T Heinzel, et al.Breast Cancer Research : BCR|June 24, 2010
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton, Xiaoyong Fu, Bryan T Hennessy, et al.Pediatric Blood & Cancer|June 21, 2022
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortiumEric S Schafer, Karen Chao, Alexandra M Stevens, et al.Breast Cancer Research and Treatment|March 11, 2011
The p160 ER co-regulators predict outcome in ER negative breast cancerMelanie Spears, Steffi Oesterreich, Ilenia Migliaccio, et al.Pageof 41